# A Study Evaluating Safety and Pharmacokinetics of VX-440 in Combination With Tezacaftor/Ivacaftor in Healthy Adult Subjects

> **NCT03486236** · PHASE1 · COMPLETED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 16 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** VX-440
- **DRUG:** TEZ
- **DRUG:** IVA
- **DRUG:** Matched Placebos

## Key facts

- **NCT ID:** NCT03486236
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-20
- **Primary completion:** 2016-09-14
- **Final completion:** 2016-09-14
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2018-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03486236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03486236, "A Study Evaluating Safety and Pharmacokinetics of VX-440 in Combination With Tezacaftor/Ivacaftor in Healthy Adult Subjects". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03486236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*